TMPyP4 exerted antitumor effects in human cervical cancer cells through activation of p38 mitogen-activated protein kinase

Ming-Jun Cheng and Yun-Gui Cao*
The cationic porphyrin, 5,10,15,20-tetra-(N-methyl-4-pyrydyl) porphine (TMPyP4), a novel type of synthetic water-soluble photosensitizer, has been recently developed as a chemotherapeutics drug for treating cancers [6]. It has been reported that TMPyP4 leads to the arrest of tumor cell growth, and induces the apoptosis of tumor cells through reducing the telomerase activity [7–9], indicating that TMPyP4 presents a potential therapeutic target in tumor cells. Therefore, it is crucial to comprehensively understand biological effects of TMPyP4 in tumor cells before it can be used for anti-cancer therapeutics. In the present study, we evaluated the effects of TMPyP4 on the proliferation and apoptosis of human cervical cancer cells and further explored its underlying mechanisms.

**Methods**

**Cell culture**

Human cervical cancer cell line Hela and human normal cervical cells (Academia Sinica Cell Bank, Shanghai, China) were grown in low-glucose Dulbecco's modified Eagle medium (Gibco BRL, Grand Island, NY, USA) supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich Chemicals, USA), 100 IU/mL penicillin, and 10 mg/mL streptomycin. Cells were cultured in a incubator with 5% CO₂ at 37 °C.

**Cell viability assay**

Cell viability was assessed using MTT assay (Bestbio Biotechnology, Shanghai, China). Briefly, fresh human cervical cancer cells and human normal cervical cells at a concentration of 5 × 10⁵ cells/well were seeded in 96-well flat-bottomed tissue culture plates (Corning Inc., Corning, NY, USA) with complete culture medium and incubated for 24 h. Following two washes with phosphate-buffered saline (PBS), cells were incubated in 100 μL culture medium containing 1, 5, 10 or 20 μM TMPyP4 for 24 h at 37 °C prior to the MTT assay. Then, a total of 10 μL MTT and 100 μL culture medium was added to each well, and incubated for 1 h at 37 °C. The optical densities of the samples were measured directly using a spectrophotometric microplate reader (Beyotime Institute of Biotechnology, Haimen, China) at a wavelength of 490 nm. Each experiment was performed in triplicate and repeated six times.

**Cell apoptosis assay**

The apoptotic cells were identified by FCM according to the published article [10]. Human cervical cancer cells and human normal cervical cells at a density of 2 × 10⁴/mL were cultured in 10% FBS-containing DMEM with 1, 5, 10 or 20 μM TMPyP4 for 24 h, respectively. Cells were harvested and washed twice with cold PBS by gentle shaking. Resuspended cells were added to 1× binding buffer and cell density was adjusted to 200,000–500,000/mL. In the dark, 5 μL of Annexin V-FITC (50 mM TRIS, 100 mM NaCl, 1% BSA, 0.02% sodium azide, pH 7.4) was added to the cell suspension in a mix of 195 μL and incubated for 10 min at room temperature before adding 190 μL 1× binding buffer and 10 μL propidium iodide (PI). Cell apoptosis was assayed using a FACSscan flow cytometry apparatus (BD Biosciences, San Jose, CA, USA) and the percentage of apoptotic cells was analyzed using FlowJo 7.6.1 software (TreeStar, Inc., Ashland, OR, USA). Each experiment was performed in triplicate and repeated six times.

**Western blot analysis**

Following the treatment with 20 μM TMPyP4 for 24 h, cells were collected for protein extraction. The examination of the expression levels of caspase-3, MK-2, PARP, p38 MAPK and p-p38 MAPK was then performed. Total protein was extracted and the bicinchoninic acid assay kit (Beyotime Institute of Biotechnology) was used to measure the protein concentration. A total of 20 μg protein was separated by SDS-PAGE and transferred onto a polyvinylidene fluoride membrane using wet transfer apparatus (Bio-Rad, Hercules, CA, USA). The membranes were then blocked with 5% skimmed milk and incubated overnight at 4 °C with the primary antibodies, followed by incubation with the secondary antibodies labeled with HRP. Next, the protein bands were visualized using an enhanced chemiluminescence kit (Millipore, Billerica, MA, USA) and the protein levels were detected using the chemiluminescence reader, ImageQuant™ LAS4000 (GE Healthcare, Pittsburgh, PA, USA). Antibodies were purchased from Santa Cruz Biotechnology, CA, USA. Band density was quantitated using Image J software (Image J 1.35, National Institute of Mental Health, USA).

**Caspase-3 activity assay**

Caspase-3 activity was analyzed using caspase-3 activity assay kits according to the manufacturer's instructions. Briefly, the reaction buffer and the specific enzyme DEVD-pNA were added to each cell plate and further cultured in an incubator for 1 h at 37 °C. The developed colorimetric reaction was measured at 405 nm in a 96-well Biorad 680 microplate reader (Bio-Rad, Hercules, CA, USA).

**Block of p38 MAPK signaling using inhibitor**

Cells were treated with p38 MAPK inhibitor SB203580 (5 μM) for 24 h followed by addition of 20 μM TMPyP4, and further incubated for 24 h. Then, cell proliferation and apoptosis were evaluated.
**Statistical analysis**
All results were analyzed using SPSS 17.0 statistical software (IBM, Armonk, NY, USA). Data are presented as the mean ± standard deviation (SD). Student’s two-tailed t test was used to determine the statistical differences between the treatment and control groups. P values were based on the two sided statistical analysis, and P < 0.05 was considered to indicate a statistically significant difference.

**Results**

**TMPyP4 inhibited the proliferation rates of human cervical cancer cells**
To investigate the roles of TMPyP4 in human cervical cancer cells, we performed the MTT assay to evaluate the changes of cell viability. It was found that TMPyP4 (IC\(_{50}\) = 16.35 μM) significantly decreased OD\(_{490}\) values of human cervical cancer cells in a dose-dependent manner compared with the control group without TMPyP4 treatment (P < 0.05) (Fig. 1a). On the other hand, OD\(_{490}\) values of human normal cervical cells were minimally affected after exposed to TMPyP4 at different concentrations (P > 0.05) (Fig. 1b). These results indicated that TMPyP4 had low cytotoxic effects on human normal cells and inhibited cell proliferation in human cervical cancer cells.

**TMPyP4 induced the apoptosis of human cervical cancer cells**
To evaluate the apoptotic effects of TMPyP4 on human cervical cancer cells, cells were respectively exposed to different concentrations of TMPyP4 for 24 h. As shown in Fig. 2a, TMPyP4 remarkably induced the apoptosis of human cervical cancer cells in a dose-dependent manner. Approximately 9.0, 15.0, 36, 55.0% of cancer cells occurred apoptosis respectively after exposed to 1, 5, 10, 20 μM TMPyP4 for 24 h, but less than 6.0% of cancer cells without TMPyP4 stimulation showed apoptosis. Next, to further ascertain the apoptotic effects of TMPyP4 on human cervical cancer cells, typical apoptotic marker caspase-3 activity was measured by commercial kits. As shown in Fig. 2b, caspase-3 activity was promoted in TMPyP4-treated human cervical cancer cells (P < 0.05), which indicated that TMPyP4 indeed triggered apoptosis in human cervical cancer cells. Nevertheless, results in Fig. 2c provided the evidence that there was no significant apoptosis in human normal cervical cells after being exposed to the indicated concentration of TMPyP4 for 24 h (P > 0.05). These findings suggested that TMPyP4 obviously induced apoptosis in human cervical cancer cells, but not in human normal cervical cells.

**TMPyP4 activated p38 MAPK signaling in human cervical cancer cells**
To determine the mechanisms underlying the promotion of cell apoptosis, we assessed the expression pattern of p38 MAPK signaling components including p38 MAPK and p-p38 MAPK by Western blot assay in human normal cervical cells and human cervical cancer cells (Fig. 3a). Western blot analysis of p38 MAPK found that p38 MAPK protein was expressed in human cervical cancer cells and human cervical cancer cells, but it showed no difference between TMPyP4 (20 μM) treated cells and non-TMPyP4 treated cells (P > 0.05). Furthermore, there was no obvious changes in protein expression of p-p38 MAPK between TMPyP4-treated normal cells and the control normal cells (P > 0.05). In contrast, the p-p38 MAPK expression level was comparatively low in human cervical cancer cells compared with normal cells, and elevated protein level of p-p38 MAPK was demonstrated in TMPyP4-treated cells in comparison with cancer cells without TMPyP4 stimulation (P < 0.05) (Fig. 3b). It was suggested that TMPyP4 could activate the p38 MAPK signaling pathway in human cervical cancer cells.
Activation of p38 MAPK signaling in human cervical cancer cells is required for TMPyP4-induced down-regulation of cell viability

Further, we examined the influence of p38 MAPK signaling on TMPyP4-induced down-regulation of cell viability in human cervical cancer cells. Cells treated with p38 MAPK signaling inhibitor SB203580 showed a decline in MK-2 protein expression, but had no effects on p-p38 MAPK expression compared to the control cells (Fig. 4a), suggesting better inhibitory efficiency of SB203580. Cell viability was promoted showing as high OD490 values in SB203580-treated cells while it was inhibited in TMPyP4-treated cells compared to the control ($P < 0.05$). However, there was no difference in cell OD490 values between SB203580-TMPyP4 co-treated cells and SB203580 treated cells ($P > 0.05$) (Fig. 4b).

Activation of p38 MAPK signaling in human cervical cancer cells is required for TMPyP4-triggered apoptosis

To further confirm whether p38 MAPK activation contributed to TMPyP4-triggered apoptosis in human cervical cancer cells, a pharmacological inhibitor of p38 MAPK, SB203580 was used in this study. It was found that pretreatment of 5 μM SB203580 remarkably attenuated the apoptotic rate (Fig. 5a) and caspase-3 activity (Fig. 5b), while TMPyP4 significantly induced apoptosis by promoting the apoptotic rate, caspase-3 activity, and PARP and caspase-3 protein expression (Fig. 5c) in human cervical cancer cells ($P < 0.05$). Moreover, the apoptotic rate, caspase-3 activity, caspase-3 and...
PARP protein expression showed no difference between SB203580-treated cells and SB203580-TMPyP4 co-treated groups ($P > 0.05$). These results indicated that p38 MAPK activation was involved in TMPyP4-induced apoptosis in human cervical cancer cells.

**Discussion**

TMPyP4, serving as a photosensitizer in PDT, has proved to play an essential role in controlling osteosarcoma [11]. Besides, TMPyP4 has been recently developed as a chemotherapeutics drug to inhibit telomerase activity through binding to and stabilizing telomeric G-quadruplex DNA in cancer cells [7–9]. Through directly interaction with telomeres, TMPyP4 can rapidly evoke antiproliferative
effects [12]. In vivo, after intratumor injection of 10 mg/kg TMPyP4 for 10 days, cervical tumor growth in nude mice was significantly inhibited without any injury to the skin and internal organs [13]. Therefore, in this study, we used this agent for investigation in cultured human cervical cancer cells to further evaluate its antitumor effects and underlying mechanism.

In the present study, treatment with various concentrations of TMPyP4 significantly induced inhibition of proliferation in human cervical cancer cells. Previous report suggested that TMPyP4 could lead to progressive telomere shortening that eventually resulted in cancer cell apoptosis [6]. Mikami-Terao et al. ever demonstrated that treatment with 100 μM TMPyP4 significantly inhibited the growth of K562 leukemic cells, with decreases of cells in the G(1) phase and increases of those in the S and G(2)/M phases after 48 h [14]. In the following study, Mikami-Terao and his team found that TMPyP4 at doses of 10, 20, 50 or 100 μM significantly inhibited the growth of retinoblastoma cell lines, Y79 and WERI-Rb1 cells. In contrast, cell apoptosis was induced by TMPyP4 in a dose-dependent manner in both cell lines, which was associated with the increased expression of phosphorylated p53 (Ser46) protein and activation of MAPK [15]. TMPyP4 at concentrations of 3, 6, 15, 30 or 60 μM significantly inhibited the proliferation and motility of human ovarian carcinoma A2780 cells but suppressed the expression levels of minichromosome maintenance protein-2 (MCM2) and carbonic anhydrase IX (CA-IX) [16]. Additionally, TMPyP4 inhibited proliferation while induced apoptosis in colon cancer cells SW480 by the suppression of Wnt/β-catenin signaling pathway [17]. More recently, a study demonstrated that, TMPyP4 at low doses less than 0.5 μM could promote the migration of human lung cancer A549 cells, HeLa, osteosarcoma U2OS and SAOS2. In contrast, TMPyP4 at high-dose larger than 2 μM inhibited cell proliferation and induced cell apoptosis in these cells [18]. These findings above provided new insights into TMPyP4 which could be developed as a possible anticancer drug.

Numerous studies have indicated that the mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in regulating cell proliferation, promoting cell cycle progression [19–21], and inducing resistance to radiotherapy and chemotherapy in tumor cells [22, 23]. In addition, p38 MAPK signaling cascade is a major pathway participating in the apoptotic pathway to suppress apoptosis of tumor cells [24, 25]. For instance, K562 leukemic cells treated with 100 μM TMPyP4 showed a decrease in c-Myc protein expression, and an obvious increase in the expression of p21 (CIP1), p57 (kip2), p38 MAPK, c-Jun N-terminal kinase, and extracellular signal-regulated kinase [14]. Most interestingly, our data showed that TMPyP4 could promote the expression level of p-p38 MAPK in human cervical cancer cells, implicating p38 MAPK activation as a potential target for TMPyP4. Also, we provided the evidence that the p38 MAPK signaling was involved in TMPyP4-induced changes in proliferation and apoptosis of human cervical cancer cells.

Conclusions

In conclusion, we not only revealed a critical role for TMPyP4 in human cervical cancer cell proliferation and apoptosis, but also explored the molecular mechanisms by which TMPyP4 contributed to its antitumor effects. Up-regulation of the p38 MAPK signaling pathway by TMPyP4 could inhibit cell proliferation while promoted cell apoptosis in human cervical cancer cells. This study provided insight into the molecular mechanism of the antitumor effects of TMPyP4, indicating the p38 MAPK signaling might be a potential therapeutic target for TMPyP4 in human cervical cancer.

Authors’ contributions

CYG was the guarantor of integrity of the entire study and was responsible for manuscript review. CMJ designed this study and took experimental studies. Both authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

This work was supported by Shanghai Medical Specialty Construction Project (ZK2015B08) and Project of Jiading District Health Bureau of Shanghai (WS201607).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 13 March 2017 Accepted: 21 June 2017

Published online: 03 July 2017

References

1. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.
2. Campos NG, Sharma M, Clark A, Kim JJ, Resch SC. Resources required for cervical cancer prevention in low- and middle-income countries. PLoS ONE. 2016;11(10):e0164000.
3. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.
4. Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y. Prognostic factors in stage IB-IIb cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 2010;101:413–7.
5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
6. Fujimori J, Matsuo T, Shimose S, Kubo T, Ishikawa M, Yasunaga Y, Ochi M. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J Orthop Res. 2011;29:1707–11.
7. Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH, Beass DJ. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther. 2002;1:565–73.
8. Rha SY, Izbiacka E, Lawrence R, Davidson K, Sun D, Moyer MP, Rodman GD, Hurley L, Von Hoff D. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin Cancer Res. 2000;6(2):987–93.
9. Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003;2(9):825–33.
10. Xia ZX, Li ZX, Zhang M, Sun LM, Zhang GF, Qiu XS. CARMA3 regulates the invasion, migration, and apoptosis of non-small cell lung cancer cells by activating NF-κB and suppressing the P38 MAPK signaling pathway. Exp Mol Pathol. 2016;100(2):353–60.
11. Mergny JL, Hélène C. G-quadruplex DNA: a target for drug design. Nat Med. 1998;4(12):1366–7.
12. Izbiacka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D, Windle BE, Hurley LH, Von Hoff DD. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. 1999;59(3):639–44.
13. Liu AH, Sun X, Wei XQ, Zhang YZ. Efficacy of multiple low-dose photodynamic TMPyP4 therapy on cervical cancer tumour growth in nude mice. Asian Pac J Cancer Prev. 2013;14(9):5371–4.
14. Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Yamada H. Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett. 2008;261(2):226–34.
15. Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Kawanot Agawa M, Ida H, Yamada H. Antitumor activity of TMPyP4 interacting G-quadruplex in retinoblastoma cell lines. Exp Eye Res. 2009;89(2):200–8.
16. Liu H, Lv C, Ding B, Wang J, Li S, Zhang Y. Antitumor activity of G-quadruplex-interactive agent TMPyP4 with photodynamic therapy in ovarian carcinoma cells. Oncol Lett. 2014;8(1):409–13.
17. Zhang YQ, Zhang YH, Xie J, Li MN, Liu ZR, Shen JY, Shi SS, Lan XY, Wang S, Cheng NL. TMPyP4-regulated cell proliferation and apoptosis through the Wnt/B-catenin signaling pathway in SW480 cells. J Recept Signal Transduct Res. 2016;36(2):167–72.
18. Zheng XH, Nie X, Liu HY, Fang YM, Zhao Y, Xia LX. TMPyP4 promotes cancer cell migration at low doses, but induces cell death at high doses. Sci Rep. 2016;6:26592.
19. Browne AJ, Göbel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD. p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death Dis. 2016;7:e2119.
20. Lin Y, Mallen-St Clair J, Wang G, Luo J, Palma-Diaz E, Lai C, Elshoff DA, Sharma S, Dubinett SM, St John M. p38 MAPK mediates epithelial–mesenchymal transition by regulating p38IP and snail in head and neck squamous cell carcinoma. Oral Oncol. 2016;60:81–9.
21. Zhang C, Shi J, Mao SY, Xu YS, Zhang D, Feng LY, Zhang B, Yan YY, Wang SC, Pan JP, Yang YP, Lin NM. Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737. J Cell Mol Med. 2015;19(2):408–17.
22. Liu CL, Chen SF, Wu MZ, Jao SW, Lin YS, Yang CY, Lee TY, Wen LW, Lan GL, Nieh S. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer. Oncotarget. 2016;7(12):14279–90.
23. Park SH, Seong MA, Lee HY. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. Oncotarget. 2016;7(7):8184–99.
24. Hui K, Yang Y, Shi K, Luo H, Duan J, An L, Wu P, CY, Shi L, Xu C. The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo. Cancer Lett. 2014;354(1):189–99.
25. Martin-Blanco E. p38 MAPK signalling cascades: ancient roles and new functions. BioEssays. 2000;22:637–45.